HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ME 2303

structure given in first source; RN given refers to (2S-cis)-isomer

Also Known As:

7-O-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)pimelyladriamcycinone; FAD 104; FAD-104; ME-2303; ME2302

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 06/01/1990 - "Thirty-five mg/kg of ME 2303 was effectively inhibited tumor growth against 3 lines, with marked efficacy against 2 lines. " 06/01/1991 - "To evaluate the cardiotoxicity of ME 2303, ECG tracings (21 patients) and Holter ECGs (9 patients) were recorded before and after the administration of ME 2303 for various malignancies (mean dose 123.8 mg/m2), and some of the electrocardiographic parameters were analyzed. "
2.	Colorectal Neoplasms (Colorectal Cancer) 06/01/1990 - "On the other hand, 50 mg/kg of ME 2303 was also effective against 4 lines tested (2 each of gastric and colorectal cancers), with marked efficacy against 3. In all, ME 2303 was more effective than doxorubicin except one of stomach cancer. "
3.	Stomach Neoplasms (Stomach Cancer) 06/01/1990 - "On the other hand, 50 mg/kg of ME 2303 was also effective against 4 lines tested (2 each of gastric and colorectal cancers), with marked efficacy against 3. In all, ME 2303 was more effective than doxorubicin except one of stomach cancer. "
4.	Myeloid Leukemia (Leukemia, Myelocytic) 01/01/1989 - "Therefore, FAD-104 may be useful in the treatment of some forms of myeloid leukemia." 01/01/1989 - "In addition, FAD-104 but not ADM induced a clonal down-grading in both normal and leukemic blast cells, and it stimulated the terminal differentiation of myeloid leukemia cells. "
5.	Cardiotoxicity 06/01/1991 - "To evaluate the cardiotoxicity of ME 2303, ECG tracings (21 patients) and Holter ECGs (9 patients) were recorded before and after the administration of ME 2303 for various malignancies (mean dose 123.8 mg/m2), and some of the electrocardiographic parameters were analyzed. " 06/01/1991 - "[Evaluation of cardiotoxicity in new anthracycline analog ME 2303. " 01/01/1993 - "Anthracyclines including SM-5887, KRN-8602, ME-2303 under studies in Japan have shown comparable or superior antitumor activities and lower cardiac toxicities compared to doxorubicin in preclinical studies and therefore the results obtained in clinical trials are expected. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Anthracyclines
3.	amrubicin
4.	morpholinoanthracycline MX2 (MX-2)